Plain-English translation of NCT06792734 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage trial testing a new drug called to see if it is safe and works well in people with B cell lymphoma that has come back or stopped responding to previous treatments. You would take this medication by mouth in two-week cycles—taking it daily for one week, then resting for one week. The research team will carefully monitor your health and track how your lymphoma responds using PET scans.
Many people with B cell lymphoma find that their cancer returns or becomes resistant to standard treatments, leaving them with limited options. This trial is designed to find out if this new treatment could offer hope to patients in that situation.
You likely qualify if…
You likely don't qualify if…
You would take the medication by mouth for one week, then take one week off, repeating this pattern throughout the trial. You would have baseline and regular follow-up scans (PET-CT scans) to check how your lymphoma is responding—initially at weeks 3, 5, and then every 3 months for the first year, and every 6 months after that. The trial focuses on finding the right dose and watching carefully for any side effects during the first two cycles (about four weeks).
AI-generated summary from trial data · Jul 8, 2026 · Not medical advice
United States